Changes in clinical trials of cancer drugs in mainland China over the decade 2009-18: a systematic review

被引：68

作者：

Li, Ning ^{[1
]}

Huang, Hui-Yao ^{[1
]}

Wu, Da-Wei ^{[1
]}

Yang, Zhi-Min ^{[3
,4
]}

Wang, Jun ^{[3
,4
]}

Wang, Jian-Sheng ^{[5
]}

Wang, Shu-Hang ^{[1
]}

Fang, Hong ^{[1
]}

Yu, Yue ^{[1
]}

Bai, Ying ^{[1
]}

Yan, Zhao ^{[6
]}

Cao, Ye ^{[7
]}

Jiang, Min ^{[8
]}

Liu, Yan-Fei ^{[9
]}

Li, Kun-Yan ^{[10
]}

Xu, Bing-He ^{[1
]}

Sun, Yan ^{[1
]}

He, Jie ^{[2
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Clin Trials Ctr, Beijing, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Thorac Surg, Beijing, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Natl Canc Ctr, Beijing, Peoples R China

[4] China Food & Drug Adm, Natl Ctr Drug Evaluat, Beijing, Peoples R China

[5] Minist Ecol & Environm Peoples Republ China, Policy Res Ctr Environm & Econ, Beijing, Peoples R China

[6] Tianjin Med Univ Canc Inst & Hosp, Clin Trial Ctr, Tianjin, Peoples R China

[7] Sun Yat Sen Univ, Clin Trial Ctr, Canc Ctr, Guangzhou, Guangdong, Peoples R China

[8] Peking Univ Canc Hosp & Inst, Natl Drug Clin Trials Inst, Beijing, Peoples R China

[9] Fudan Univ, Shanghai Canc Ctr, Clin Trial Ctr, Shanghai, Peoples R China

[10] Hunan Canc Hosp, Clin Trial Ctr, Changsha, Hunan, Peoples R China

来源：

LANCET ONCOLOGY | 2019年 / 20卷 / 11期

关键词：

ARM;

D O I：

10.1016/S1470-2045(19)30491-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

As a result of recent, substantial capacity building, a new landscape for cancer drug trials is emerging in China. However, data on the characteristics of cancer drug trials, and how they have changed over time, are scarce. Based on clinical trials published on the China Food and Drug Administration Registration and Information Disclosure Platform for Drug Clinical Studies, we aimed to systematically review changes over time in clinical trials of cancer drugs in mainland China from 2009 to 2018, to provide insight on the effectiveness of the pharmaceutical industry and identify unmet clinical needs of stakeholders. A total of 1493 trials of 751 newly tested cancer drugs were initiated. Increases over time were observed for the annual number of initiated trials, newly tested drugs, and newly added leading clinical trial units, with a sharp increase after 2016. Of the 1385 trials in which cancer types were identified, solid tumours (325 [23%] trials), non-small-cell lung cancer (232 [17%]), and lymphoma (126 [9%]) were the most common. A markedly uneven distribution was also observed in the geography of leading units with the largest number of leading units located in east China (50 [41%]) and the smallest number located in southwest China (4 [3%]). The growth trends we observed illustrate the progress in and increasing capability of cancer drug research and development achieved in mainland China over the decade from 2009. The low number of clinical trials on tumours with epidemiological characteristics unique to the Chinese population and the unbalanced geographical distribution of leading clinical trial units will provide potential targets for policy makers and other stakeholders. Further research efforts should address cancers uniquely relevant to Chinese populations, globally rare cancers, and the balance between equitable drug access, efficiency, and sustainability of cancer drug research and development in mainland China.

引用

页码：E619 / E626

页数：8

共 31 条

[1] [Anonymous], 2016, STAT COUNC GEN OFF O
[2] [Anonymous], 2008, NAT 11 5 YEAR PLAN A
[3] [Anonymous], 2017, OP GEN ADM ENC DRUG
[4] [Anonymous], ANN GEN ADM WORK PLA
[5] [Anonymous], 2018, ANN STAT DRUG ADM ST
[6] [Anonymous], J CLIN ONCOL
[7] [Anonymous], ANN GEN ADM SOL OP R
[8] [Anonymous], 2017, JIAK GOUJ ZHENGC TIX
[9] [Anonymous], 2015, STAT COUNC OP REF EX
[10] [Anonymous], 2013, DEEP REF DRUG REV AP

← 1 2 3 4 →